Anti-Obesity Prescription Drugs Market 2028 By Mechanism of Action, Drug Class, Distribution Channel | The Insight Partners

Anti-Obesity Prescription Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Mechanism of Action (Peripherally Acting Drugs, Centrally Acting Drugs); Drug Class (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Report Code: TIPRE00020942 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

MARKET INTRODUCTION

Obesity is a public health problem also a genetic and chronic metabolic disease which involves accumulation of excessive or abnormal fat in the body. Chronic conditions such as hypertension, cardiovascular diseases, diabetics, ventilatory failure, obstructive sleep apnea, cancer, and others are associated with obesity. Increasing prevalence of obesity among children and adults is affectation a threat and developing nations also it has a major impact on population longevity and health related expense.

MARKET DYNAMICS

Changing lifestyle leading to decrease in exercise practice among people, product developments, and increase in the obesity population is expected to drive the demand for anti-obesity drugs in the near future. However, the availability of alternative therapies and the possible side effects of anti-obesity drugs are expected to hamper the market growth.

MARKET SCOPE

The "Anti-Obesity Prescription Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of anti-obesity prescription drugs market with detailed market segmentation by drug class, mechanism of action, and distribution channel. The anti-obesity prescription drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in anti-obesity prescription drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The anti-obesity prescription drugs market is segmented on the basis of drug class, mechanism of action, and distribution channel. Based on drug class, the market is segmented as bupropion and naltrexone, orlistat, lorcaserin, phentermine and topiramate, and liraglutide. Based on mechanism of action, the market is segmented as peripherally acting drugs and centrally acting drugs. By distribution channel, the market is segmented as hospital pharmacy, retail pharmacy, and online pharmacy.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the anti-obesity prescription drugs market based onvarious segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anti-obesity prescription drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting anti-obesity prescription drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anti-obesity prescription drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the anti-obesity prescription drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anti-obesity prescription drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for anti-obesity prescription drugs in the global market. Below mentioned is the list of few companies engaged in the anti-obesity prescription drugs market.

The report also includes the profiles of key players in anti-obesity prescription drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and drug class, mechanism of action, and distribution channel s offered, financial information of last 3 years, key development in past five years.

  •   BRISTOL-MYERS SQUIBB CO.
  •   TAKEDA PHARMACEUTICAL
  •   EISAI COMPANY
  •   GLAXOSMITHKLINE PLC
  •   PFIZER INC
  •   SHIONOGI USA INC
  •   VIVUS INC
  •   ZAFGEN INC
  •   NORGINE BV
  •   BOEHRINGER INGELHEIM GMBH.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-Obesity Prescription Drugs Market - By Mechanism of Action
1.3.2 Anti-Obesity Prescription Drugs Market - By Drug Class
1.3.3 Anti-Obesity Prescription Drugs Market - By Distribution Channel
1.3.4 Anti-Obesity Prescription Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-OBESITY PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-OBESITY PRESCRIPTION DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-OBESITY PRESCRIPTION DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - MECHANISM OF ACTION
7.1. OVERVIEW
7.2. MECHANISM OF ACTION MARKET FORECASTS AND ANALYSIS
7.3. PERIPHERALLY ACTING DRUGS
7.3.1. Overview
7.3.2. Peripherally Acting Drugs Market Forecast and Analysis
7.4. CENTRALLY ACTING DRUGS
7.4.1. Overview
7.4.2. Centrally Acting Drugs Market Forecast and Analysis
8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. BUPROPION AND NALTREXONE
8.3.1. Overview
8.3.2. Bupropion and Naltrexone Market Forecast and Analysis
8.4. ORLISTAT
8.4.1. Overview
8.4.2. Orlistat Market Forecast and Analysis
8.5. LORCASERIN
8.5.1. Overview
8.5.2. Lorcaserin Market Forecast and Analysis
8.6. PHENTERMINE AND TOPIRAMATE
8.6.1. Overview
8.6.2. Phentermine and Topiramate Market Forecast and Analysis
8.7. LIRAGLUTIDE
8.7.1. Overview
8.7.2. Liraglutide Market Forecast and Analysis
9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anti-Obesity Prescription Drugs Market Overview
10.1.2 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.1.3 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.1.4 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.1.5 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anti-Obesity Prescription Drugs Market
10.1.6.1.1 United States Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.1.2 United States Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.1.3 United States Anti-Obesity Prescription Drugs Market by Distribution Channel
10.1.6.2 Canada Anti-Obesity Prescription Drugs Market
10.1.6.2.1 Canada Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.2.2 Canada Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.2.3 Canada Anti-Obesity Prescription Drugs Market by Distribution Channel
10.1.6.3 Mexico Anti-Obesity Prescription Drugs Market
10.1.6.3.1 Mexico Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.3.2 Mexico Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.3.3 Mexico Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Anti-Obesity Prescription Drugs Market Overview
10.2.2 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.2.3 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.2.4 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anti-Obesity Prescription Drugs Market
10.2.6.1.1 Germany Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.1.2 Germany Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.1.3 Germany Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.2 France Anti-Obesity Prescription Drugs Market
10.2.6.2.1 France Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.2.2 France Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.2.3 France Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.3 Italy Anti-Obesity Prescription Drugs Market
10.2.6.3.1 Italy Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.3.2 Italy Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.3.3 Italy Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.4 Spain Anti-Obesity Prescription Drugs Market
10.2.6.4.1 Spain Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.4.2 Spain Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.4.3 Spain Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Anti-Obesity Prescription Drugs Market
10.2.6.5.1 United Kingdom Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.5.2 United Kingdom Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.5.3 United Kingdom Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Anti-Obesity Prescription Drugs Market
10.2.6.6.1 Rest of Europe Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.6.2 Rest of Europe Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.6.3 Rest of Europe Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anti-Obesity Prescription Drugs Market Overview
10.3.2 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.3.4 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anti-Obesity Prescription Drugs Market
10.3.6.1.1 Australia Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.1.2 Australia Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.1.3 Australia Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.2 China Anti-Obesity Prescription Drugs Market
10.3.6.2.1 China Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.2.2 China Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.2.3 China Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.3 India Anti-Obesity Prescription Drugs Market
10.3.6.3.1 India Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.3.2 India Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.3.3 India Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.4 Japan Anti-Obesity Prescription Drugs Market
10.3.6.4.1 Japan Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.4.2 Japan Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.4.3 Japan Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.5 South Korea Anti-Obesity Prescription Drugs Market
10.3.6.5.1 South Korea Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.5.2 South Korea Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.5.3 South Korea Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.6.2 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Overview
10.4.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.4.4 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anti-Obesity Prescription Drugs Market
10.4.6.1.1 South Africa Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.1.2 South Africa Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.1.3 South Africa Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Anti-Obesity Prescription Drugs Market
10.4.6.2.1 Saudi Arabia Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.2.2 Saudi Arabia Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.2.3 Saudi Arabia Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.3 U.A.E Anti-Obesity Prescription Drugs Market
10.4.6.3.1 U.A.E Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.3.2 U.A.E Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.3.3 U.A.E Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.4.2 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anti-Obesity Prescription Drugs Market Overview
10.5.2 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.5.3 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.5.4 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anti-Obesity Prescription Drugs Market
10.5.6.1.1 Brazil Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.1.2 Brazil Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.1.3 Brazil Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5.6.2 Argentina Anti-Obesity Prescription Drugs Market
10.5.6.2.1 Argentina Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.2.2 Argentina Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.2.3 Argentina Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Anti-Obesity Prescription Drugs Market
10.5.6.3.1 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.3.2 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.3.3 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, KEY COMPANY PROFILES
13.1. BRISTOL-MYERS SQUIBB CO.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. TAKEDA PHARMACEUTICAL
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. EISAI COMPANY
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE PLC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. PFIZER INC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. SHIONOGI USA INC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. VIVUS INC
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ZAFGEN INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. NORGINE BV
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BOEHRINGER INGELHEIM GMBH.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. BRISTOL-MYERS SQUIBB CO.
2. TAKEDA PHARMACEUTICAL
3. EISAI COMPANY
4. GLAXOSMITHKLINE PLC
5. PFIZER INC
6. SHIONOGI USA INC
7. VIVUS INC
8. ZAFGEN INC
9. NORGINE BV
10. BOEHRINGER INGELHEIM GMBH.
11. 7TM PHARMA
12. ZYDUS CADILA
13. AKRIMAX PHARMACEUTICALS
14. ZEALAND PHARMA
15. ARROWHEAD RESEARCH
TIPRE00020942
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.


Speak To Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550
    GET FREE SAMPLE PDF

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount